Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePRNewsWire • 12/23/25
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPRNewsWire • 12/10/25
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPRNewsWire • 12/09/25
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPRNewsWire • 12/04/25
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)PRNewsWire • 12/01/25
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingPRNewsWire • 11/25/25
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationPRNewsWire • 11/21/25
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial LaunchPRNewsWire • 10/20/25
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesPRNewsWire • 10/17/25
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™PRNewsWire • 10/16/25
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern EuropePRNewsWire • 10/07/25
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementPRNewsWire • 09/10/25
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementPRNewsWire • 09/09/25
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchPRNewsWire • 08/22/25
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 08/12/25
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraPRNewsWire • 07/15/25
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 05/14/25
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 02/14/25
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 02/14/25
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesPRNewsWire • 02/06/25
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025PRNewsWire • 01/07/25